Item 9 Labs Corp. Logo

Item 9 Labs Corp.

INLB

(1.0)
Stock Price

0,00 USD

-76.44% ROA

-42.07% ROE

-0x PER

Market Cap.

70.181,00 USD

44.94% DER

0% Yield

-143.14% NPM

Item 9 Labs Corp. Stock Analysis

Item 9 Labs Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Item 9 Labs Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock maintains a fair debt to equity ratio (65%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

Negative ROE (-53.38%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-72.04%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Item 9 Labs Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Item 9 Labs Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Item 9 Labs Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Item 9 Labs Corp. Revenue
Year Revenue Growth
2011 0
2012 892.187 100%
2013 341.991 -160.88%
2014 179.494 -90.53%
2015 113.022 -58.81%
2016 324.026 65.12%
2017 243.926 -32.84%
2018 1.375.295 82.26%
2019 4.933.960 72.13%
2020 8.121.733 39.25%
2021 21.937.227 62.98%
2022 21.756.997 -0.83%
2023 20.089.500 -8.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Item 9 Labs Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Item 9 Labs Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 23.112
2012 4.103.167 99.44%
2013 1.310.376 -213.13%
2014 962.155 -36.19%
2015 869.649 -10.64%
2016 729.382 -19.23%
2017 157.493 -363.12%
2018 394.399 60.07%
2019 4.116.827 90.42%
2020 5.521.131 25.44%
2021 9.890.917 44.18%
2022 17.018.106 41.88%
2023 12.127.988 -40.32%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Item 9 Labs Corp. EBITDA
Year EBITDA Growth
2011 -23.112
2012 -3.717.408 99.38%
2013 -4.264.858 12.84%
2014 -1.041.755 -309.39%
2015 -1.072.926 2.91%
2016 -595.960 -80.03%
2017 5.715 10528%
2018 -611.787 100.93%
2019 -3.170.959 80.71%
2020 -4.346.778 27.05%
2021 -4.349.758 0.07%
2022 -11.197.692 61.15%
2023 -9.450.636 -18.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Item 9 Labs Corp. Gross Profit
Year Gross Profit Growth
2011 0
2012 474.406 100%
2013 198.169 -139.39%
2014 63.831 -210.46%
2015 -4.284 1589.99%
2016 165.704 102.59%
2017 163.248 -1.5%
2018 357.186 54.3%
2019 2.377.771 84.98%
2020 3.295.774 27.85%
2021 8.612.943 61.73%
2022 7.311.728 -17.8%
2023 11.275.260 35.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Item 9 Labs Corp. Net Profit
Year Net Profit Growth
2011 -23.112
2012 -4.087.714 99.43%
2013 -3.325.069 -22.94%
2014 -17.082.226 80.53%
2015 -4.740.684 -260.33%
2016 -3.125.536 -51.68%
2017 -266.571 -1072.5%
2018 -642.282 58.5%
2019 -10.631.157 93.96%
2020 -12.299.657 13.57%
2021 -16.191.961 24.04%
2022 -31.179.053 48.07%
2023 -23.644.776 -31.86%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Item 9 Labs Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 -3 100%
2013 -2 -200%
2014 -7 83.33%
2015 -1 -500%
2016 -1 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Item 9 Labs Corp. Free Cashflow
Year Free Cashflow Growth
2011 -14.922
2011 -14.922 0%
2012 -985.961 98.49%
2013 -389.078 -153.41%
2014 -754.598 48.44%
2015 -747.559 -0.94%
2016 -339.724 -120.05%
2017 68.906 593.03%
2018 -1.518.393 104.54%
2019 -8.851.040 82.85%
2020 -1.547.532 -471.95%
2021 -8.231.798 81.2%
2022 -7.712.702 -6.73%
2023 87.292 8935.52%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Item 9 Labs Corp. Operating Cashflow
Year Operating Cashflow Growth
2011 -14.922
2011 -14.922 0%
2012 -966.175 98.46%
2013 -353.544 -173.28%
2014 -738.598 52.13%
2015 -740.849 0.3%
2016 -339.724 -118.07%
2017 68.906 593.03%
2018 -975.762 107.06%
2019 -2.393.428 59.23%
2020 -1.141.416 -109.69%
2021 -5.989.581 80.94%
2022 -2.254.362 -165.69%
2023 150.137 1601.54%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Item 9 Labs Corp. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2011 0 0%
2012 19.786 100%
2013 35.534 44.32%
2014 16.000 -122.09%
2015 6.710 -138.45%
2016 0 0%
2017 0 0%
2018 542.631 100%
2019 6.457.612 91.6%
2020 406.116 -1490.09%
2021 2.242.217 81.89%
2022 5.458.340 58.92%
2023 62.845 -8585.4%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Item 9 Labs Corp. Equity
Year Equity Growth
2011 -22.812
2011 -22.812 0%
2012 -2.285.000 99%
2013 -2.937.851 22.22%
2014 -2.636.308 -11.44%
2015 -4.984.712 47.11%
2016 -2.073.163 -140.44%
2017 -2.230.083 7.04%
2018 2.617.509 185.2%
2019 7.336.446 64.32%
2020 8.015.249 8.47%
2021 86.101.443 90.69%
2022 61.940.595 -39.01%
2023 52.644.304 -17.66%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Item 9 Labs Corp. Assets
Year Assets Growth
2011 20.300
2011 20.300 0%
2012 1.139.182 98.22%
2013 442.455 -157.47%
2014 508.656 13.01%
2015 112.665 -351.48%
2016 89.215 -26.28%
2017 108.640 17.88%
2018 3.512.740 96.91%
2019 14.474.320 75.73%
2020 20.663.769 29.95%
2021 116.809.133 82.31%
2022 110.761.619 -5.46%
2023 112.015.496 1.12%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Item 9 Labs Corp. Liabilities
Year Liabilities Growth
2011 43.112
2011 43.112 0%
2012 3.424.182 98.74%
2013 3.380.306 -1.3%
2014 3.144.964 -7.48%
2015 5.097.377 38.3%
2016 2.162.378 -135.73%
2017 2.338.723 7.54%
2018 895.231 -161.24%
2019 7.137.874 87.46%
2020 12.648.520 43.57%
2021 30.707.690 58.81%
2022 48.821.024 37.1%
2023 59.371.192 17.77%

Item 9 Labs Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.23
Net Income per Share
-0.33
Price to Earning Ratio
-0x
Price To Sales Ratio
0x
POCF Ratio
-0
PFCF Ratio
-0.01
Price to Book Ratio
0
EV to Sales
1.28
EV Over EBITDA
-2.49
EV to Operating CashFlow
-12.34
EV to FreeCashFlow
-3.61
Earnings Yield
-3258.32
FreeCashFlow Yield
-109.9
Market Cap
0,00 Bil.
Enterprise Value
0,03 Bil.
Graham Number
2.18
Graham NetNet
-0.49

Income Statement Metrics

Net Income per Share
-0.33
Income Quality
0.07
ROE
-0.42
Return On Assets
-0.28
Return On Capital Employed
-0.33
Net Income per EBT
1
EBT Per Ebit
1.35
Ebit per Revenue
-1.06
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.78
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.14
Gross Profit Margin
0.34
Operating Profit Margin
-1.06
Pretax Profit Margin
-1.43
Net Profit Margin
-1.43

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.08
Capex to Operating CashFlow
-2.42
Capex to Revenue
0.25
Capex to Depreciation
2.84
Return on Invested Capital
-0.15
Return on Tangible Assets
-0.76
Days Sales Outstanding
9.84
Days Payables Outstanding
162.27
Days of Inventory on Hand
62.27
Receivables Turnover
37.11
Payables Turnover
2.25
Inventory Turnover
5.86
Capex per Share
0.06

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,65
Tangible Book Value per Share
-0.08
Shareholders Equity per Share
0.65
Interest Debt per Share
0.36
Debt to Equity
0.45
Debt to Assets
0.25
Net Debt to EBITDA
-2.48
Current Ratio
0.09
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,05 Bil.
Invested Capital
54900806
Working Capital
-0,04 Bil.
Intangibles to Total Assets
0.63
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
4427786.5
Debt to Market Cap
396.76

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Item 9 Labs Corp. Dividends
Year Dividends Growth

Item 9 Labs Corp. Profile

About Item 9 Labs Corp.

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.

CEO
Mr. Robert E. Mikkelsen
Employee
97
Address
2727 North 3rd Street
Phoenix, 85004

Item 9 Labs Corp. Executives & BODs

Item 9 Labs Corp. Executives & BODs
# Name Age
1 Mr. Robert E. Mikkelsen
Secretary, Treasurer & Chief Financial Officer
70
2 Mr. Christopher Leland Wolven
Chief Operating Officer
70
3 Mr. Jeffrey I. Rassas
Strategic Advisor & Director
70
4 Ms. Jayne Levy
Senior Vice President of Communications
70
5 Kyle Jennings
Vice President of Marketing
70
6 Mr. Mark Busch
Senior Vice President of Corporate Development
70
7 Mr. Cory Carter
Senior Vice President of Cultivation
70

Item 9 Labs Corp. Competitors